Rx only · Solution · Ophthalmic

Apraclonidine

Apraclonidine Hydrochloride

1 ACTIVE SUPPLIER — US

openFDA · updated weekly

US1 NDCs
1 active makers

UKComing
soon

CAComing
soon

AUComing
soon

EUComing
soon

ATCS01EA03

RxCUI (US)14845

US makers1 labelers

Packages2

DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$9.643

Latest avg · Jul 22, 2026

+39%

Since Jun 18, 2025

Active US suppliers

100%

Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

374

Rx · 2026 Q1

2.3K

Units dispensed

+14%

Rx vs. year ago

Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Labeler	Type	Packages	Status
Sandoz Inc	unknown	2	SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

Apr 13, 2022
RECALLRecall (Class II): Aparaclonidine Ophthalmic Solution 0.5% as base, 0.5%, 5 mL bottle, Rx only, MFG:Sandoz Pharma, NDC 61314-665-05
cGMP deviations: Temperature abuse — Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office — USA nationwide.